Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity

I. R. MacGregor, J. M. Ferguson, L. F. McLaughlin, T. Burnouf, C. V. Prowse

研究成果: 雜誌貢獻文章

20 引文 (Scopus)

摘要

A non-stasis canine model of thrombogenicity has been used to evaluate batches of high purity factor IX concentrates from 4 manufacturers and a conventional prothrombin complex concentrate (PCC). Platelets, activated partial thromboplastin time (APTT), fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A (FPA) were monitored before and after infusion of concentrate. Changes in FPA were found to be the most sensitive and reproducible indicator of thrombogenicity after infusion of batches of the PCC at doses of between 60 and 180 IU/kg, with a dose related delayed increase in FPA occurring. Total FPA generated after 100-120 IU/kg of 3 batches of PCC over the 3 h time course was 9-12 times that generated after albumin infusion. In contrast the amounts of FPA generated after 200 IU/kg of the 4 high purity factor IX products were in all cases similar to albumin infusion. It was noted that some batches of high purity concentrates had short NAPTTs indicating that current in vitro tests for potential thrombogenicity may be misleading in predicting the effects of these concentrates in vivo.
原文英語
頁(從 - 到)609-613
頁數5
期刊Thrombosis and Haemostasis
66
發行號5
出版狀態已發佈 - 1991
對外發佈Yes

指紋

Fibrinopeptide A
Canidae
Albumins
Fibrin Fibrinogen Degradation Products
Factor IX
Partial Thromboplastin Time
Blood Platelets
prothrombin complex concentrates

ASJC Scopus subject areas

  • Hematology

引用此文

Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity. / MacGregor, I. R.; Ferguson, J. M.; McLaughlin, L. F.; Burnouf, T.; Prowse, C. V.

於: Thrombosis and Haemostasis, 卷 66, 編號 5, 1991, p. 609-613.

研究成果: 雜誌貢獻文章

MacGregor, I. R. ; Ferguson, J. M. ; McLaughlin, L. F. ; Burnouf, T. ; Prowse, C. V. / Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity. 於: Thrombosis and Haemostasis. 1991 ; 卷 66, 編號 5. 頁 609-613.
@article{b0eb7b53727c45669922a8cd752150e3,
title = "Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity",
abstract = "A non-stasis canine model of thrombogenicity has been used to evaluate batches of high purity factor IX concentrates from 4 manufacturers and a conventional prothrombin complex concentrate (PCC). Platelets, activated partial thromboplastin time (APTT), fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A (FPA) were monitored before and after infusion of concentrate. Changes in FPA were found to be the most sensitive and reproducible indicator of thrombogenicity after infusion of batches of the PCC at doses of between 60 and 180 IU/kg, with a dose related delayed increase in FPA occurring. Total FPA generated after 100-120 IU/kg of 3 batches of PCC over the 3 h time course was 9-12 times that generated after albumin infusion. In contrast the amounts of FPA generated after 200 IU/kg of the 4 high purity factor IX products were in all cases similar to albumin infusion. It was noted that some batches of high purity concentrates had short NAPTTs indicating that current in vitro tests for potential thrombogenicity may be misleading in predicting the effects of these concentrates in vivo.",
author = "MacGregor, {I. R.} and Ferguson, {J. M.} and McLaughlin, {L. F.} and T. Burnouf and Prowse, {C. V.}",
year = "1991",
language = "English",
volume = "66",
pages = "609--613",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "5",

}

TY - JOUR

T1 - Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity

AU - MacGregor, I. R.

AU - Ferguson, J. M.

AU - McLaughlin, L. F.

AU - Burnouf, T.

AU - Prowse, C. V.

PY - 1991

Y1 - 1991

N2 - A non-stasis canine model of thrombogenicity has been used to evaluate batches of high purity factor IX concentrates from 4 manufacturers and a conventional prothrombin complex concentrate (PCC). Platelets, activated partial thromboplastin time (APTT), fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A (FPA) were monitored before and after infusion of concentrate. Changes in FPA were found to be the most sensitive and reproducible indicator of thrombogenicity after infusion of batches of the PCC at doses of between 60 and 180 IU/kg, with a dose related delayed increase in FPA occurring. Total FPA generated after 100-120 IU/kg of 3 batches of PCC over the 3 h time course was 9-12 times that generated after albumin infusion. In contrast the amounts of FPA generated after 200 IU/kg of the 4 high purity factor IX products were in all cases similar to albumin infusion. It was noted that some batches of high purity concentrates had short NAPTTs indicating that current in vitro tests for potential thrombogenicity may be misleading in predicting the effects of these concentrates in vivo.

AB - A non-stasis canine model of thrombogenicity has been used to evaluate batches of high purity factor IX concentrates from 4 manufacturers and a conventional prothrombin complex concentrate (PCC). Platelets, activated partial thromboplastin time (APTT), fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A (FPA) were monitored before and after infusion of concentrate. Changes in FPA were found to be the most sensitive and reproducible indicator of thrombogenicity after infusion of batches of the PCC at doses of between 60 and 180 IU/kg, with a dose related delayed increase in FPA occurring. Total FPA generated after 100-120 IU/kg of 3 batches of PCC over the 3 h time course was 9-12 times that generated after albumin infusion. In contrast the amounts of FPA generated after 200 IU/kg of the 4 high purity factor IX products were in all cases similar to albumin infusion. It was noted that some batches of high purity concentrates had short NAPTTs indicating that current in vitro tests for potential thrombogenicity may be misleading in predicting the effects of these concentrates in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0026050751&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026050751&partnerID=8YFLogxK

M3 - Article

C2 - 1803625

AN - SCOPUS:0026050751

VL - 66

SP - 609

EP - 613

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 5

ER -